{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-047253","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2021-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.425709+00:00","generated_at":"2026-06-29T05:15:26.532378+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Finch Therapeutics appoints Marc Blaustein as COO effective Sept 8","bullets":["Marc Blaustein appointed COO, effective September 8, 2021.","Base salary of $400,000; target bonus of 40% of base salary; options for 150,000 shares vesting over 4 years.","Blaustein brings 20+ years biopharma experience, including roles at Dyax, Alkermes, and as CEO of NED Biosystems.","CEO Mark Smith says Blaustein's operational expertise will be valuable as Finch enters next phase of growth.","Severance includes 9 months salary (non-CIC) or 12 months salary (CIC) plus equity acceleration."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-047253","json":"https://secwatch.observer/filing/0001564590-21-047253.json","markdown":"https://secwatch.observer/filing/0001564590-21-047253.md","text":"https://secwatch.observer/filing/0001564590-21-047253.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000156459021047253/0001564590-21-047253-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000156459021047253/fnch-8k_20210908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T05:15:26.532378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d474c65b30","claim":"Marc Blaustein was appointed as Chief Operating Officer at Finch Therapeutics Group, Inc..","evidence_excerpt":"appointed Marc Blaustein to serve as the Company’s Chief Operating Officer, effective September 8, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000156459021047253/0001564590-21-047253-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}